InflaRx NV
InflaRx NV (IFRX) is a clinical-stage biotechnology company developing targeted therapies that modulate the complement system, principally a C5a‑directed monoclonal antibody. The firm focuses on inflammatory and immune‑mediated conditions where excessive complement activation is implicated. As a small‑cap, research‑heavy company with a market capitalisation around $92M, InflaRx’s value is closely tied to clinical trial outcomes, regulatory decisions and financing capacity. Investors should be aware of the high technical and regulatory risks inherent to drug development: early clinical success does not guarantee regulatory approval or commercial viability. Liquidity can be limited and share price volatility significant. This summary is educational and not investment advice; suitability depends on an investor’s objectives, time horizon and risk tolerance. Always consider reading company filings, monitoring trial updates and consulting a regulated financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying InflaRx's stock with a target price of $9.5, indicating significant growth potential.
Financial Health
InflaRx NV has low revenue and a modest cash flow, indicating financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IFRX
German Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Progress and value depend heavily on trial outcomes and regulatory milestones; this creates opportunity but also significant binary risk.
Pipeline-driven moves
Share performance tends to follow study readouts and approvals, so updates can cause sharp moves; diversification helps manage this volatility.
Market and funding
As a small-cap biotech, financing and partnerships matter for execution; funding gaps or delays can materially affect development timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
